Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Cancer: Starving sarcomas into submission A drug that inhibits blood vessel growth offers a potentially promising treatment for a class of tumors with a poor prognosis. Sarcomas form in bone and connective tissue, and patients with advanced disease have a five-year survival rate of less than 10%. Re...

Full description

Bibliographic Details
Main Authors: Zhichao Liao, Feng Li, Chao Zhang, Lei Zhu, Yehui Shi, Gang Zhao, Xu Bai, Shafat Hassan, Xinyue Liu, Ting Li, Peipei Xing, Jun Zhao, Jin Zhang, Ruwei Xing, Sheng Teng, Yun Yang, Kexin Chen, Jilong Yang
Format: Article
Language:English
Published: Nature Publishing Group 2019-02-01
Series:Experimental and Molecular Medicine
Online Access:https://doi.org/10.1038/s12276-019-0221-7

Internet

https://doi.org/10.1038/s12276-019-0221-7

Similar Items